HISTORY
Nearly 30 years of development and partnership
Nearly 30 years of development and partnership
For nearly three decades, MorphoSys has been devoted to discovering and developing promising novel therapies for some of the world’s most serious diseases.
Our story began with a specific technology that first positioned us as invaluable pharmaceutical partners—and then empowered our evolution into a fully integrated biopharmaceutical company.
For more about our history, visit morphosys.com/company/history
1992
Founded by Managing Director Simon Moroney in Munich, Germany
1993-2011
Advancing antibody science to develop novel and innovative approaches to treating cancer
1997-2017
Developed licensing agreements with partners including Novartis, Janssen, and Pfizer
Since 2007
Developing proprietary drug candidates through partnerships with GSK, Xencor, and I-Mab Biopharma, among others
2018
Nasdaq IPO and establishment of MorphoSys US Inc.
2019
Appointed Jean-Paul Kress CEO; established US subsidiary in Boston, with David Trexler as President of MorphoSys US
December 2019
Submission of Biologics License Application for tafasitamab-cxix in R/R DLBCL to the FDA
January 2020
MorphoSys and Incyte sign Global Collaboration and License Agreement for tafasitamab-cxix
February 2020
MorphoSys initiates Expanded Access Program for tafasitamab-cxix in the US
March 2020
MorphoSys receives Priority Review of its biologics license application (FDA, US)
July 2020
FDA approves MONJUVI® (tafasitamab-cxix)